Elite in X-Linked Hypophosphatemia

Peter Kamenicky

Paris, FR 
Elite in X-Linked Hypophosphatemia
Paris, FR 
OverviewLocationsClinical Research

Overview

Peter Kamenicky practices in Paris, France. Mr. Kamenicky is rated as an Elite expert by MediFind in the treatment of X-Linked Hypophosphatemia. His top areas of expertise are Hypophosphatemia, X-Linked Hypophosphatemia, Rickets, Endoscopic Transnasal Transsphenoidal Surgery, and Parathyroidectomy.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 23 articles and participated in 1 clinical trial in the study of X-Linked Hypophosphatemia.

Gender
Male

Locations

Paris, 94276, France
Other Locations
Le Kremlin Bicêtre, France
Orsay, France
78 Rue Du Général Leclerc, Rouez, 94270, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological
Study Drug: rhPTH(1-84)
Study Phase: Phase 4
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: May 20, 2022
Intervention Type: Drug
Study Drug: Burosumab
Study Phase: Phase 3
View 1 Less Clinical Trial

116 Total Publications

Advances in the Clinical Management of Parathyroid Disorders: Report from the 2024 Workshop by the ESE Educational Program on Parathyroid Disorders.
Advances in the Clinical Management of Parathyroid Disorders: Report from the 2024 Workshop by the ESE Educational Program on Parathyroid Disorders.
Journal: European journal of endocrinology
Published: July 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kamenicky's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 16 Advanced Conditions
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile